01 Increasing Adoption of Rapid and Portable Molecular Testing Platforms The point-of-care molecular diagnostics market is moving toward compact testing systems that can deliver molecular results close to the patient without depending entirely on centralized laboratories. Portable PCR platforms, integrated sample-to-result workflows, and cartridge-based systems are improving turnaround times and supporting use across hospitals, urgent care centers, physician offices, decentralized laboratories, and remote healthcare settings. In February 2026, the FDA granted CLIA waiver for the LEX Diagnostics VELO Respiratory Test, supporting broader use of rapid molecular respiratory testing in decentralized care settings.
02 Growing Integration of Multiplex and Connected Molecular Diagnostic Solutions Diagnostic platforms are increasingly combining multiplex detection with automated workflows and digital connectivity to provide broader clinical information from a single patient sample. Multiplex molecular testing can differentiate pathogens with overlapping symptoms, while connected systems enable results to be shared with healthcare records and remote-care platforms, improving the speed and coordination of clinical decision-making. In February 2025, Aptitude received U.S. FDA Emergency Use Authorization for its Metrix COVID/Flu multiplex molecular test, combining rapid molecular detection with point-of-care and over-the-counter testing capabilities.
01 Rising Burden of Infectious Diseases Increases Need for Accessible Molecular Diagnostics The continued prevalence of respiratory and other infectious diseases is increasing the need for accessible diagnostic solutions across hospitals, outpatient facilities, urgent care centers, and community healthcare settings. This underlying clinical need supports continued demand for point-of-care molecular diagnostic platforms.
01 High Costs of Molecular Diagnostic Systems and Consumables Can Limit Adoption Point-of-care molecular platforms require investment in analyzers, cartridges, reagents, quality-control procedures, connectivity infrastructure, and operator training. Recurring consumable costs can further increase the total cost of testing, making advanced molecular systems difficult to deploy in healthcare facilities with constrained budgets, particularly in low-resource and emerging markets.
01 Expansion of Point-of-Care Molecular Diagnostics Across Women's Health and Preventive Screening Creates New Growth Opportunities The expansion of molecular testing into women's health, sexually transmitted infections, cervical cancer screening, and preventive diagnostics is creating new opportunities beyond traditional infectious disease applications.
01 Maintaining Accuracy and Regulatory Compliance Across Decentralized Testing Environments Creates Challenges Expanding molecular diagnostics beyond centralized laboratories requires consistent analytical performance despite differences in operators, sample handling, environmental conditions, and healthcare infrastructure. Manufacturers must demonstrate reliable accuracy while meeting regulatory and quality requirements, making validation, workflow simplification, quality control, and operator training critical to large-scale deployment.
May 2026 Abbott expanded its ID NOW molecular diagnostics platform with enhanced respiratory testing capabilities. The updated solutions support rapid point-of-care molecular detection and improve access to near-patient diagnostic testing in clinical settings.
March 2026 Roche expanded its cobas liat molecular testing portfolio with additional point-of-care diagnostic applications. The platform supports fast molecular detection of infectious diseases through compact, automated testing workflows.
January 2026 Cepheid expanded its GeneXpert point-of-care molecular diagnostics portfolio with new assay developments for infectious disease testing. The solutions strengthen decentralized testing capabilities across hospitals, clinics, and community healthcare settings.
September 2025 bioMérieux expanded its BioFire molecular diagnostics ecosystem with new respiratory and infectious disease testing capabilities. The company continued advancing multiplex PCR-based solutions designed for rapid clinical decision-making.